Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors

This publication has 47 references indexed in Scilit:

• Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasmaTAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD)
  Thrombosis and Haemostasis, 2006
• Vascular complications of pancreatitis
  Anz Journal of Surgery, 2005
• Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
  Trends in Pharmacological Sciences, 2004
• Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays
  British Journal of Haematology, 2004
• A Kinetic Analysis of the Tissue Plasminogen Activator and DSPAα1 Cofactor Activities of Untreated and TAFIa-treated Soluble Fibrin Degradation Products of Varying Size
  Journal of Biological Chemistry, 2001
• A Steady-state Template Model That Describes the Kinetics of Fibrin-stimulated [Glu1]- and [Lys78]Plasminogen Activation by Native tissue-type Plasminogen Activator and Variants That Lack Either the Finger or Kringle-2 Domain
  Journal of Biological Chemistry, 1997
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex
  Published by Elsevier ,1996
• An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits
  Biochemical and Biophysical Research Communications, 1989
• Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator
  Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1986
• Natural inhibitors of fibrinolysis
  Journal of Clinical Pathology, 1980